| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA880: Tezepelumab for treating severe asthma |
|
Medicine details |
|
| Medicine name | tezepelumab (Tezspire®) |
| Formulation | subcutaneous injection |
| Reference number | 3844 |
| Indication | Add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Respiratory system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 30/09/2022 |
| NICE guidance | |